Atlas FDA

ACCESS(R) HYBRITECH PSA ASSAY

FDA premarket approval P850048/S016 · decided 2000-02-24

Approval details

PMA number
P850048
Supplement
S016
Supplement type
Normal 180 Day Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
ACCESS(R) HYBRITECH PSA ASSAY
Generic name
PROSTATE-SPECIFIC ANTIGEN (PSA) FOR MANAGEMENT OF PROSTATE CANCERS
Applicant
Beckman Coulter, Inc.
Date received
1999-10-18
Decision date
2000-02-24
Days to decision
129 days
Decision code
APPR
Product code
LTJ
Advisory committee
Immunology
Expedited review
No
Location
Brea, CA
Statement
Approval for addition of the Access Hybritech PSA Assay on the Access Immunoassay analyzer to other approved instrument platforms.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Access BNP II (K252169)Beckman Coulter, Inc.2026-03-24
Access anti-HBc IgM (K254059)Beckman Coulter, Inc.2026-03-13
Access anti-HBc Total (K253687)Beckman Coulter, Inc.2026-02-19
Access anti-HAV IgM (K251995)Beckman Coulter, Inc.2026-01-27
Access Rubella IgG (K250588)Beckman Coulter, Inc.2025-11-17
iQ200 Series (K252580)Beckman Coulter, Inc.2025-09-10
Access anti-HAV (K243846)Beckman Coulter, Inc.2025-09-09
MicroScan Dried Gram-Negative MIC/Combo Panels with Cefepime (CPE) (0.12-64 µg/mL) (MicroScan) (K243804)Beckman Coulter, Inc.2025-08-20